Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with advanced AML that harbors IDH1 mutation
Patients are relapsed from or refractory to at least 1 previous line of therapy
Good kidney and liver function
Male or female patients
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Women must have a negative serum pregnancy test within 7 days prior to the first dose of study drug or be surgically or biologically sterile or postmenopausal
You may not be if
Previously treated with any prior mIDH1 targeted therapy
Extramedullary disease only
History of clinically significant or active cardiac disease
Active clinically significant infection
Unresolved chronic toxicity of previous AML treatment
Taking known strong cytochrome P450 (CYP) 2C8 inducers or inhibitors
